IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

NCT07672483 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

95

Enrollment

NIH

Sponsor class

Conditions

Relapsed Solid Tumor Malignancies
Refractory Solid Tumor Malignancies

Interventions

BIOLOGICAL: IL-12 GEMys
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Cetuximab

Sponsor

National Cancer Institute (NCI)